Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Glioblastoma 154Brain Neoplasms 73Glioma 69Central Nervous System Neoplasms 50Gliosarcoma 46Astrocytoma 37Melanoma 36Oligodendroglioma 29Neuroblastoma 17Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 11Sarcoma, Ewing 10Sarcoma 10Neoplasms 10Medulloblastoma 10Recurrence 9Neuroendocrine Tumors 9Lymphoma 8Ependymoma 8Breast Neoplasms 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Diffuse Intrinsic Pontine Glioma 7Colorectal Neoplasms 7Carcinoma, Neuroendocrine 6Adenoma, Islet Cell 6Uveal Melanoma 5Spinal Cord Neoplasms 5Pheochromocytoma 5

Interventions

antineoplaston AS 2-1 1antineoplaston A10 1Temozolomide 1Microarray Analysis 1DNA Methylation 1Complementary Therapies 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Growth Hormone-Secreting Pituitary Adenoma × Temozolomide × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡